CL2017002351A1 - Agente terapéutico para disfunción del lóbulo frontal - Google Patents
Agente terapéutico para disfunción del lóbulo frontalInfo
- Publication number
- CL2017002351A1 CL2017002351A1 CL2017002351A CL2017002351A CL2017002351A1 CL 2017002351 A1 CL2017002351 A1 CL 2017002351A1 CL 2017002351 A CL2017002351 A CL 2017002351A CL 2017002351 A CL2017002351 A CL 2017002351A CL 2017002351 A1 CL2017002351 A1 CL 2017002351A1
- Authority
- CL
- Chile
- Prior art keywords
- cognitive impairment
- disease
- lewy
- frontal lobe
- dementia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>La presente invención proporciona un agente terapéutico y/o preventivo, por ejemplo, para disfunción del lóbulo frontal (por ejemplo, alteración cognitiva (por ejemplo, alteración cognitiva en enfermedad de Parkinson, alteración cognitiva causada por estrés crónico, demencia con cuerpos de Lewy, parálisis supranuclear progresiva, demencia frontotemporal, y similares), y otros), enfermedad de cuerpos de Lewy (por ejemplo, alteración cognitiva en enfermedad de Parkinson, enfermedad difusa de cuerpos de Lewy, demencia con cuerpos de Lewy, trastorno del movimiento asociado con enfermedad de cuerpos de Lewy, y similares), y otros, que contiene un compuesto representado por la fórmula (I) o una de sus sales farmacéuticamente aceptables como un ingrediente activo.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015055532 | 2015-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002351A1 true CL2017002351A1 (es) | 2018-03-16 |
Family
ID=56919157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002351A CL2017002351A1 (es) | 2015-03-19 | 2017-09-15 | Agente terapéutico para disfunción del lóbulo frontal |
Country Status (39)
Country | Link |
---|---|
US (2) | US20180042910A1 (es) |
EP (1) | EP3270923B1 (es) |
JP (1) | JP6869893B2 (es) |
KR (1) | KR20170129764A (es) |
CN (1) | CN107405341A (es) |
AR (1) | AR103972A1 (es) |
AU (1) | AU2016234211B2 (es) |
BR (1) | BR112017018165A2 (es) |
CA (1) | CA2978426A1 (es) |
CL (1) | CL2017002351A1 (es) |
CO (1) | CO2017008814A2 (es) |
CR (1) | CR20170405A (es) |
CY (1) | CY1124459T1 (es) |
DK (1) | DK3270923T3 (es) |
DO (1) | DOP2017000206A (es) |
EA (1) | EA032511B1 (es) |
EC (1) | ECSP17069712A (es) |
ES (1) | ES2884846T3 (es) |
GE (1) | GEP20197007B (es) |
HK (1) | HK1249059A1 (es) |
HR (1) | HRP20211340T1 (es) |
HU (1) | HUE055387T2 (es) |
IL (1) | IL254196A0 (es) |
JO (1) | JO3544B1 (es) |
LT (1) | LT3270923T (es) |
MX (1) | MX2017012020A (es) |
MY (1) | MY196076A (es) |
PE (1) | PE20171621A1 (es) |
PL (1) | PL3270923T3 (es) |
PT (1) | PT3270923T (es) |
RS (1) | RS62311B1 (es) |
SG (1) | SG11201707012YA (es) |
SI (1) | SI3270923T1 (es) |
SV (1) | SV2017005527A (es) |
TN (1) | TN2017000369A1 (es) |
TW (1) | TWI723012B (es) |
UA (1) | UA123578C2 (es) |
WO (1) | WO2016148308A1 (es) |
ZA (1) | ZA201706136B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE325610T1 (de) | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
CN1902196B (zh) | 2003-12-26 | 2010-12-29 | 协和发酵麒麟株式会社 | 噻唑衍生物 |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
WO2012060844A1 (en) | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en active Application Filing
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Application Discontinuation
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
- 2016-03-18 MX MX2017012020A patent/MX2017012020A/es unknown
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja active Active
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
-
2017
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2018
- 2018-07-11 HK HK18108966.3A patent/HK1249059A1/zh unknown
-
2021
- 2021-08-20 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
PH12018501976A1 (en) | Arginase inhibitors and their therapeutic applications | |
UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
GT201700223A (es) | Imidazopirazinonas como inhibidores de pde 1 | |
CO2018012485A2 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
BR112017005231A2 (pt) | formulações eutéticas de cloridrato de ciclobenzaprina | |
CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
SV2016005305A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
CL2017002351A1 (es) | Agente terapéutico para disfunción del lóbulo frontal | |
CR20170426A (es) | Inhibidores de bace 1 | |
CO2020001792A2 (es) | Combinaciones farmacéuticas | |
CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
CL2020000362A1 (es) | Nuevos compuestos. | |
MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
JP2018508540A5 (es) | ||
JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll |